Earnings ·
Cibus, Inc. reported second quarter 2026 financial results showing a net loss of $22.1 million, or $0.29 per share…
CBUSCibus, Inc.
Cibus, Inc. reported second quarter 2026 financial results showing a net loss of $22.1 million, or $0.29 per share, compared to a $26.6 million loss in the prior year period. Revenue increased to $0.994 million from $0.933 million year-over-year. Cash and cash equivalents rose to $20.4 million as quarterly net cash usage declined 19% sequentially and 31% annually, driven by cost reduction initiatives. The company updated its Rice trait development with Interoc, expanding the relationship scope to five traits, while maintaining launch targets for Latin America in 2028 and the U.S. in 2029. Regulatory progress includes EU alignment on treating precise gene-edited crops as conventional breeding. Cibus operates in the agricultural biotechnology industry, developing crop traits using precise genome editing technology.